GH (Guardant Health) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GH Guardant Health Inc GH
65 GF Score
Price $179.46
GF Value $66.66
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Guardant Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Guardant Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $28 Mil. Guardant Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $1,669 Mil. Guardant Health's annualized EBITDA for the quarter that ended in Jun. 2026 was $-436 Mil. Guardant Health's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was -3.89.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Guardant Health's Debt-to-EBITDA or its related term are showing as below:

GH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.57   Med: -3.12   Max: -0.01
Current: -4.13

During the past 10 years, the highest Debt-to-EBITDA Ratio of Guardant Health was -0.01. The lowest was -4.57. And the median was -3.12.

GH's Debt-to-EBITDA is ranked worse than
100% of 118 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.475 vs GH: -4.13

Guardant Health  (NAS:GH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Guardant Health Debt-to-EBITDA Related Terms

Guardant Health Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Guardant Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guardant Health Debt-to-EBITDA Chart

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Guardant Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

GH vs MEDP, DGX, LH: Debt-to-EBITDA Comparison

For the Diagnostics & Research subindustry, Guardant Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guardant Health Debt-to-EBITDA vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Guardant Health's Debt-to-EBITDA falls into.


GH
65GF Score
Guardant Health Inc GH
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guardant Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Guardant Health's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(27.679 + 1682.463) / -373.907
=-4.57

Guardant Health's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(27.758 + 1669.255) / -436.2
=-3.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Guardant Health (GH) Overvalued in 2026?

Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued. The current stock price of $179.46 is trading 169.2% above its estimated GF Value™ of $66.66. GuruFocus considers Guardant Health to be Significantly Overvalued.

Key valuation signals for GH:

  • Debt-to-EBITDA:
  • GF Value™: $66.66 vs. price of $179.46 (169.2% above fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guardant Health Business Description

Other Exchanges 1GH:Italy5GH:Germany
Address 3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
65GF Score

Get the complete analysis for GH

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$179.46
Price
$66.66
GF Value